activity
20002018
most citedStructure of Intratumor Heterogeneity: Is Cancer Hedging Its Bets?

9 citations · 33 across the 16 of their papers we have counts for

collaborators

17 papers

q-bio.PE2018★ 2 cited

In Silico Implementation of Evolutionary Paradigm in Therapy Design: Towards Anti-Cancer Therapy as Darwinian Process

Branislav Brutovsky, Denis Horvath

In here presented in silico study we suggest a way how to implement the evolutionary principles into anti-cancer therapy design. We hypothesize that instead of its ongoing supervis…

q-bio.TO2017

A New Conceptual Framework for the Therapy by Optimized Multidimensional Pulses of Therapeutic Activity. The case of Multiple Myeloma Model

Denis Horváth, Branislav Brutovsky

We developed simulation methodology to assess eventual therapeutic efficiency of exogenous multiparametric changes in a four-component cellular system described by the system of or…

q-bio.PE2017★ 6 cited

Toward understanding of the role of reversibility of phenotypic switching in the evolution of resistance to therapy

Denis Horvath, Branislav Brutovsky

Reversibility of state transitions is intensively studied topic in many scientific disciplines over many years. In cell biology, it plays an important role in epigenetic variation…

physics.data-an2014

Self-organized manifold learning and heuristic charting via adaptive metrics

Denis Horvath, Jozef Ulicny, Branislav Brutovsky

Classical metric and non-metric multidimensional scaling (MDS) variants are widely known manifold learning (ML) methods which enable construction of low dimensional representation…

q-bio.QM2014

Towards Inverse Modeling of Intratumoral Heterogeneity

Branislav Brutovsky, Denis Horvath

Development of resistance limits efficiency of present anticancer therapies and preventing it remains big challenge in cancer research. It is accepted, at intuitive level, that the…

q-bio.PE2013★ 9 cited

Structure of Intratumor Heterogeneity: Is Cancer Hedging Its Bets?

B. Brutovsky, D. Horvath

Development of resistance limits transferability of most anticancer therapies into curative treatment and understanding mechanisms beyond it remains a big challenge. Many high reso…